Tampa pharma firm advances equity offering
March 21, 2019 - Oragenics Inc. expects to receive $12.5 million in gross proceeds in a new equity offering. The company will sell stock and warrants to buy stock at 75 cents a share. Oragenics (NYSE American: OGEN), based in Tampa, is developing antibiotics and treatments for oral mucositis.